THEIR MYOPIA
Introducing Essilor® Stellest® lenses, the first and only FDA market authorized spectacle lens to slow the progression of nearsightedness in children.*1
*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment. 1Essilor International, data on file (2025)
THEIR MYOPIA
Introducing Essilor® Stellest® lenses, the first and only FDA market authorized spectacle lens to slow the progression of nearsightedness in children.*1
*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment. 1Essilor International, data on file (2025)









